Compare ADMA Biologics Inc (ADMA) vs ArcelorMittal SA (MT) Price & Performance

ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.

The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.

ArcelorMittal (MT) trades at $63.15, down 0.39% on the day, with a bullish technical signal supported by moving averages. The stock shows strong earnings momentum, beating estimates for three consecutive quarters, and maintains a reasonable valuation with a P/E of 17.11 and P/S of 0.81. Recent news highlights expansion initiatives, a share buyback program, and a strategic AI collaboration with AWS to drive efficiency and lower-carbon steel production.

The outlook for MT is positive, driven by operational expansions and favorable steel import policies in Europe and the US, though risks include high capital expenditures and exposure to Chinese market weakness. Analyst sentiment is predominantly bullish with 50% buy ratings, supporting potential upside if earnings growth continues.